Institution
University of Belgrade
Education•Belgrade, Serbia•
About: University of Belgrade is a education organization based out in Belgrade, Serbia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 20667 authors who have published 47148 publications receiving 896243 citations. The organization is also known as: Univerzitet u Beogradu & Belgrade University.
Topics: Population, Large Hadron Collider, Adsorption, Lepton, Higgs boson
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, bottom-up and top-down building stock models have been used to estimate the baseline energy demand of the existing building stock, explore the technical and economic effects of different CO2 emission reduction strategies over time, including the impact of new technologies, and identify the effect of emission reduction strategy on indoor environmental quality.
813 citations
••
TL;DR: In this paper, Bhaskar and Lakshmikantham introduced the concept of a mixed g-monotone mapping and proved coupled coincidence and coupled common fixed point theorems for such nonlinear contractive mappings in partially ordered complete metric spaces.
Abstract: We introduce the concept of a mixed g -monotone mapping and prove coupled coincidence and coupled common fixed point theorems for such nonlinear contractive mappings in partially ordered complete metric spaces. Presented theorems are generalizations of the recent fixed point theorems due to Bhaskar and Lakshmikantham [T.G. Bhaskar, V. Lakshmikantham, Fixed point theorems in partially ordered metric spaces and applications, Nonlinear Anal. TMA 65 (2006) 1379–1393] and include several recent developments.
799 citations
••
29 Mar 2012
TL;DR: In this article, the authors reported results from searches for the standard model Higgs boson in proton-proton collisions at square root(s) = 7 TeV in five decay modes: gamma pair, b-quark pair, tau lepton pair, W pair, and Z pair.
Abstract: Combined results are reported from searches for the standard model Higgs boson in proton-proton collisions at sqrt(s)=7 TeV in five Higgs boson decay modes: gamma pair, b-quark pair, tau lepton pair, W pair, and Z pair. The explored Higgs boson mass range is 110-600 GeV. The analysed data correspond to an integrated luminosity of 4.6-4.8 inverse femtobarns. The expected excluded mass range in the absence of the standard model Higgs boson is 118-543 GeV at 95% CL. The observed results exclude the standard model Higgs boson in the mass range 127-600 GeV at 95% CL, and in the mass range 129-525 GeV at 99% CL. An excess of events above the expected standard model background is observed at the low end of the explored mass range making the observed limits weaker than expected in the absence of a signal. The largest excess, with a local significance of 3.1 sigma, is observed for a Higgs boson mass hypothesis of 124 GeV. The global significance of observing an excess with a local significance greater than 3.1 sigma anywhere in the search range 110-600 (110-145) GeV is estimated to be 1.5 sigma (2.1 sigma). More data are required to ascertain the origin of this excess.
786 citations
••
University of Zurich1, University Hospital of Lausanne2, European Organisation for Research and Treatment of Cancer3, University of Edinburgh4, Sunnybrook Health Sciences Centre5, Catholic University of Korea6, University of Texas MD Anderson Cancer Center7, University of Bonn8, University of Belgrade9, Goethe University Frankfurt10, German Cancer Research Center11, Samsung Medical Center12, University Hospital Regensburg13, University Medical Center Freiburg14, University of Szeged15, Academy for Urban School Leadership16, Ludwig Maximilian University of Munich17, Seoul National University Bundang Hospital18, University of Alabama at Birmingham19, Harvard University20, Erasmus University Rotterdam21, Merck KGaA22
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.
Abstract: Summary Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. Methods In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries. Eligible patients (newly diagnosed, histologically proven supratentorial glioblastoma, methylated MGMT promoter, and age ≥18 years) were stratified for prognostic Radiation Therapy Oncology Group recursive partitioning analysis class and geographic region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg intravenously twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group). Patients and investigators were unmasked to treatment allocation. Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 months or until disease progression or unacceptable toxic effects. The primary endpoint was overall survival. We analysed survival outcomes by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00689221. Findings Overall, 3471 patients were screened. Of these patients, 3060 had tumour MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008, and May 12, 2011. Median overall survival was 26·3 months (95% CI 23·8–28·8) in the cilengitide group and 26·3 months (23·9–34·7) in the control group (hazard ratio 1·02, 95% CI 0·81–1·29, p=0·86). None of the predefined clinical subgroups showed a benefit from cilengitide. We noted no overall additional toxic effects with cilengitide treatment. The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]). Interpretation The addition of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug. Nevertheless, integrins remain a potential treatment target for glioblastoma. Funding Merck KGaA, Darmstadt, Germany.
778 citations
••
TL;DR: In this article, the transverse momentum balance in dijet and γ/Z+jets events is used to measure the jet energy response in the CMS detector, as well as the transversal momentum resolution.
Abstract: Measurements of the jet energy calibration and transverse momentum resolution in CMS are presented, performed with a data sample collected in proton-proton collisions at a centre-of-mass energy of 7TeV, corresponding to an integrated luminosity of 36pb−1. The transverse momentum balance in dijet and γ/Z+jets events is used to measure the jet energy response in the CMS detector, as well as the transverse momentum resolution. The results are presented for three different methods to reconstruct jets: a calorimeter-based approach, the ``Jet-Plus-Track'' approach, which improves the measurement of calorimeter jets by exploiting the associated tracks, and the ``Particle Flow'' approach, which attempts to reconstruct individually each particle in the event, prior to the jet clustering, based on information from all relevant subdetectors
750 citations
Authors
Showing all 21031 results
Name | H-index | Papers | Citations |
---|---|---|---|
John J.V. McMurray | 178 | 1389 | 184502 |
Barry Halliwell | 173 | 662 | 159518 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Guenakh Mitselmakher | 165 | 1951 | 164435 |
H. Eugene Stanley | 154 | 1190 | 122321 |
Jovan Milosevic | 152 | 1433 | 106802 |
Nikolay Tyurin | 142 | 1270 | 101170 |
Andrew J. Lees | 140 | 877 | 91605 |
Y. B. Hsiung | 138 | 1258 | 94278 |
Lihong V. Wang | 136 | 1118 | 72482 |
Maria Spiropulu | 135 | 1455 | 96674 |
C. Haber | 135 | 1507 | 98014 |
Gabor Istvan Veres | 135 | 1349 | 96104 |
Francisco Matorras | 134 | 1428 | 94627 |
Aldo P. Maggioni | 134 | 940 | 90242 |